348

CHAPTER-4

349

4. BIBLIOGRAPHY

1. Roth B. Design of dihydrofolate reductase inhibitors from X-ray crystal

structures. Fed Proc 1986; 45: 2765-2772.

2. Falco EA, Hitchings GH, Russell PB, Vanderwerff H. Antimalarials as

antagonists of purines and pteroylglutamic acid. Nature 1949; 164: 107.

3. Burchall JJ, Hitchings GH. Inhibitor binding analysis of dihydrofolate

reductases from various species. Mol Pharmacol 1965; 1: 126-136.

4. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The

pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309:

1094-1104.

5. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR.

Methotrexate induces clinical and histologic remission in patients with

refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-356.

6. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN et

al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med

1985; 312: 818-822.

7. Weinstein GD, Frost P. Methotrexate for psoriasis: a new therapeutic

schedule. Arch Dermatol 1971; 103: 33-38.

8. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT.

Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological

outcome. J Rheumatol 1995; 22: 241-245.

9. Mullarkey MF, Blumenstein BA, Andrade WP, Bailey GA, Olason I, Wetzel

CE. Methotrexate in the treatment of corticosteroid-dependent asthma. A

double-blind crossover study. N Engl J Med 1988; 318: 603-607.

350

10. Green E, Demos CH. In folate antagonists as therapeutic agents. Sirotnak FM,

Burchall JJ, Ensminger WD, Montgomery JA, editors. Academic Press:

Orlando. 1984; 2: 192-249.

11. Ferone R, Burchall JJ, Hitchings GH. Plasmodium berghei dihydrofolate

reductase isolation, properties, and inhibition by antifolates. Mol Pharmacol

1969; 5: 49-59.

12. Kan SC, Siddiqui WA. Comparative studies on dihydrofolate reductases from

Plasmodium falciparum and Aotus trivirgatus. J Protozool 1979; 26: 660-664.

13. Maroun J. Clinical response to trimetrexate as sole therapy for non-small cell

lung cancer. Semin Oncol 1988; 15: 17-21.

14. Allegra CJ, Chabner BA, Tuazon CU, Arakaki DO, Baird B, Drake JC et al.

Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients

with the acquired immunodeficiency syndrome. N Engl J Med 1987; 317:

978-985.

15. Blaney JM, Hansch C, Silipo C, Vittoria A. Structure-activity relationships of

dihydrofolated reductase inhibitors, structure-activity relationships of

dihydrofolated reductase inhibitors. Chem Rev 1984; 84: 333-407.

16. Kisliuk RL. Folate biochemistry in relation to antifolate selectivity. In

antifolate drugs in cancer therapy. Jackman AL, editor. Humana Press,

Totowa, NJ. 1999; 13-36.

17. Thien KR, Blair JA, Leeming RJ, Cooke WT, Melikian V. Serum folates in

man. J Clin Pathol 1977; 30: 438-448.

18. Grem JL, Takimoto CH, Multani P, Chu E, Ryan D, Chabner BA et al. In

cancer chemotherapy and biological response modifiers; Pinedo HM, Longo

DL, Chabner BA, editors. New York: Elsevier Science; 1999; 1-38.

351

19. Barredo J, Moran RG. Determinants of antifolate cytotoxicity:

folylpolyglutamate synthetase activity during cellular proliferation and

development. Mol Pharmacol 1992; 42: 687-694.

20. Johnson TB, Nair MG, Galivan J. Role of folylpolyglutamate synthetase in the

regulation of methotrexate polyglutamate formation in H35 hepatoma cells.

Cancer Res 1988; 48: 2426-2431.

21. Allegra CJ. Antifolates. In cancer chemotherapy: Principles and practice.

Chabner B, Collins J, editors. Philadelphia: Lippincott ; 1990; 110-153.

22. Balinska M, Galivan J, Coward JK. Efflux of methotrexate and its

polyglutamate derivatives from hepatic cells in vitro. Cancer Res 1981; 41:

2751-2756.

23. Coward JK, Parameswaran KN, Cashmore AR, Bertino JR. 7,8-

Dihydropteroyl oligo-γ-L-glutamates. Synthesis and kinetic studies with

purified dihydrofolate reductase from mammalian sources. Biochemistry

1974; 13: 3899-3903.

24. Kumar P, Kisliuk RL, Gaumont Y, Freisheim JH, Nair MG. Inhibition of

human dihydrofolate reductase by antifolyl polyglutamates. Biochem

Pharmacol 1989; 38: 541-543.

25. Kisliuk RL, Gaumont Y, Baugh CM, Galivan J, Maley GF, Maley F. In

chemistry and biology of pteridines. Kisliuk RL, Brown GM, editors. North-

Holland: New York. Elsevier. 1979; 261.

26. Allegra CJ, Chabner BA, Tuazon CU, Arakaki OD, Baird B, Drake JC et al.

Treatment of Pneumocystis carinii pneumonia with trimetrexate in acquired

immunodeficiency syndrome (AIDS). Semin Oncol 1988; 15: 46-49.

352

27. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of

phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate

and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985; 82:

4881-4885.

28. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4-

carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate

deaminase by polyglutamates of methotrexate and oxidized folates and by 5-

aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986; 236:

193-200.

29. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of

methotrexate. Increased adenosine release at inflamed sites diminishes

leukocyte accumulation in an in vivo model of inflammation. J Clin Invest

1993; 92: 2675-2682.

30. Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Lipsky JJ. Plasma and rectal

adenosine in inflammatory bowel disease: Effect of methotrexate. Inflamm

Bowel Dis 1999; 5: 167-173.

31. Urakawa K, Mihara M, Suzuki T, Kawamura A, Akamatsu K, Takeda Y,

Kamatani N. Polyglutamation of antifolates is not required for induction of

extracellular release of adenosine or expression of their anti-inflammatory

effects. Immunopharmacology 2000; 48: 137-144.

32. Seeger DR, Cosulich DB, Smith JM, Hultquist ME. Analogs of

pteroylglutamic acid. III. 4-Amino derivatives. J Am Chem Soc 1949; 71:

1753-1758.

353

33. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP.

Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion

of activated peripheral T cells. J Clin Invest 1998; 102: 322-328.

34. Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanisms

of action of methotrexate. Immunopharmacology 2000; 47: 247-257.

35. Bertino JR, Mini E, Sobrero A, Moroson BA, Love T, Jastreboff M et al.

Advances in Enzyme Regulation. 24; Weber G. editor. New York: Pergamon;

1985; 3-11.

36. Bertino JR, Srimatkandada S, Carman MD, Mini E, Jastreboff M, Moroson

BA et al. Mechanism of drug resistance in human leukemia. Haematol Blood

Transfus 1985; 29: 90-95.

37. Elslager EF, Davoll J: Synthesis of fused pyrimidines as folate antagonists. In:

Castle RN, Townsend LR, editors. Lectures in Heterocyclic Chemistry, vol 2.

Orem, Utah, Hetero, 1974; S97–S133.

38. Elslager EF, Johnson JL, Werbel LM. Folate antagonists. 20. Synthesis and

antitumor and antimalarial properties of trimetrexate and related 6-

[(phenylamino)methyl]-2,4-quinazolinediamines. J Med Chem 1983; 26:

1753-1760.

39. Bertino JR, Sawicki WL, Moroson BA, Cashmore AR, Elslager EF. 2,4-

Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (TMQ), a

potent non-classical folate antagonist inhibitor-I: Effect of dihydrofolate

reductase and growth of rodent tumors in vitro and in vivo. Biochem

Pharmacol 1979; 28: 1983-1987.

40. Weir EC, Cashmore AR, Dreyer RN, Graham ML, Hsiao N, Moroson BA et

al. Pharmacology and toxicity of a potent ”nonclassical” 2,4-diamino

354

quinazoline folate antagonist, trimetrexate, in normal dogs. Cancer Res 1982;

42: 1696-1702.

41. Lin JT, Cashmore AR, Baker M, Dreyer RN, Ernstoff M, Marsh JC et al.

Phase I studies with trimetrexate: clinical pharmacology, analytical

methodology, and pharmacokinetics. Cancer Res 1987; 47: 609-616.

42. Landis NT. Initial triservice formulary ready for use. Pharmacoeconomic

center will issue quarterly updates. Am J Hosp Pharm 1994; 51: 591.

43. Grivsky EM, Lee S, Sigel CW, Duch DS, Nichol CA. Synthesis and antitumor

activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]

pyrimidine. J Med Chem 1980; 23: 327-329.

44. Duch DS, Edelstein MP, Bowers SW, Nichol CA. Biochemical and

chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxylbenzyl)-5-

methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of

dihydrofolate reductase. Cancer Res 1982; 42: 3987-3994.

45. Kovacs JA, Allegra CJ, Swan JC, Drake JC, Parrillo JE, Chabner BA et al.

Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-

soluble antifolate. Antimicrob Agents Chemother 1988; 32: 430-433.

46. Perkins W, Williams REA, Vestey JP, Tidman MJ, Layton AM, Cunliffe WJ

et al. A multicentre 12-week open study of a lipid-soluble folate antagonist,

piritrexim in severe psoriasis. Br J Dermatol 1993; 129: 584-589.

47. Guzzo C, Benik K, Lazarus G, Johnson J, Weinstein G. Treatment of psoriasis

with piritrexim, a lipid-soluble folate antagonist. Arch Dermatol 1991; 127:

511-514.

355

48. Cramer SM, Schornagel JH, Kalghatgi KK, Bertino JR, Horvath C.

Occurrence and significance of D-methotrexate as a contaminant of

commercial methotrexate. Cancer Res 1984; 44: 1843-1846.

49. Gready JE. Advances in Pharmacology and Chemotherapy. New York,

Academic Press. 1980; 17: 37-102.

50. McCormack JJ. Dihydrofolate reductase inhibitors as potential drugs. Med

Res Rev 1981; 1: 303-331.

51. Rosowsky A. Chemistry and biological activity of antifolates. Prog Med

Chem 1989; 26: 1-252.

52. Baker BR. Design of Active-Site-Directed Irreversible Enzyme Inhibitors.

New York, Wiley. 1967; 199.

53. Montgomery JA, Piper JR. Folate Antagonists as Therapeutic Agents;

Sirotnak FM, Burchall JJ, Ensminger WB, Montgomery JA, editors. Orlando,

Academic Press: 1984; 219-260.

54. Piper JR, McCaleb GS, Montgomery JA, Kisliuk RL, Gaumont Y, Sirotnak

FM. Syntheses and antifolate activity of 5-methyl-5-deaza analogs of

aminopterin, methotrexate, folic acid and N10-methylfolic acid. J Med Chem

1986; 29: 1080-1087.

55. Rosowsky A, Chen KKN. Methotrexate analogs. 4. 7-Methyl derivatives of

methotrexate and dichloromethotrexate. New synthesis and some biological

studies. J Med Chem 1974; 17: 1308-1311.

56. McGuire JJ, Bolanowska WE, Coward JK, Sherwood RF, Russell CA,

Felschow DM. Biochemical and biological properties of methotrexate analogs

containing D-glutamic acid or D-erythro, threo-4-fluoroglutamic acid.

Biochem Pharmacol 1991; 42: 2400-2403.

356

57. Roth B, Aig E. 2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8.

The 3,4,5-triethyl isostere of trimethoprim. A study of specificity. J Med

Chem 1987; 30: 1998-2004.

58. El-Hamamsy MHRI, Smith AW, Thompson AS, Threadgill MD. Structure-

based design, synthesis and preliminary evaluation of selective inhibitors of

dihydrofolate reductase from Mycobacterium tuberculosis. Bioorg Med Chem

2007; 15: 4552-4576.

59. Otzen T, Wempe EG, Kunz B, Bartels R, Yvetot GL, Hansel W et al. Folate-

synthesizing enzyme system as target for development of inhibitors and

inhibitor combinations against Candida albicans- synthesis and biological

activity of new 2,4-diaminopyrimidines and 4'-substituted 4-aminodiphenyl

sulfones. J Med Chem 2004; 47: 240-253.

60. Hawser S, Lociuro S, Islam K. Dihydrofolate reductase inhibitors as

antibacterial agents. Biochem Pharmacol 2006; 71: 941-948.

61. Huang YL, Lin CF, Lee YJ, Li WW, Chao TC, Valeriy AB et al. Non-

classical antifolates, 5-(N-phenylpyrrolidin-3-yl)-2,4,6-triaminopyrimidines

and 2,4-diamino-6(5H)-oxopyrimidines, synthesis and antitumor studies.

Bioorg Med Chem 2003; 11: 145-157.

62. Richardson ML, Croughton KA, Matthews CS, Stevens MFG. Structural

studies on bioactive compounds. 39. Biological consequences of the structural

modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-

3-nitrophenyl)-6-ethylpyrimidines (‘benzoprims'). J Med Chem 2004; 47:

4105-4108.

63. Stevens MFG, Phillip KS, Rathbone DL, O'Shea DM, Queener SF, Schwalbe

CH et al. Structural studies on bioactive compounds. 28. Selective activity of

357

triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii

dihydrofolate reductase. J Med Chem 1997; 40: 1886-1893.

64. Robson C, Meek MA, Grunwaldt JD, Lambert PA, Queener SF, Schmidt D et

al. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: Activity as

inhibitors of dihydrofolate reductase from Pneumocystis carinii and

Toxoplasma gondii and as antitumor agents. J Med Chem 1997; 40: 3040-

3048.

65. Chan DCM, Laughton CA, Queener SF, Stevens MFG. Structural studies on

bioactive compounds. 34. Design, synthesis, and biological evaluation of

triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii

dihydrofolate reductase. J Med Chem 2001; 44: 2555-2564.

66. Richter WE, McCormack JJ. Inhibition of mammalian dihydrofolate reductase

by selected 2,4-diaminoquinazolines and related compounds. J Med Chem

1974; 17: 943-947.

67. Rogan PK, William GJB. The structure of the dihydrofolate reductase

inhibitor 2,4,6-triamino-5-chloroquinazoline. Acta Cryst Sect B 1980; 36:

2358-2362.

68. Rosowsky A, Mota CE, Wright JE, Queener SF. 2,4-Diamino-5-

chloroquinazoline analogs of trimetrexate and piritrexim: Synthesis and

antifolate activity. J Med Chem 1994; 37: 4522-4528.

69. Rosowsky A, Mota CE, Queener SF, Waltham M, Abali EE, Bertino JR. 2,4-

Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate

reductase with a site-directed mutation at position 22 and of the dihydrofolate

reductases from Pneumocystis carinii and Toxoplasma gondii. J Med Chem

1995; 38: 745-752.

358

70. Gangjee A, Vidwans AP, Vasudevan A, Queener SF, Kisliuk RL, Cody V et

al. Structure-based design and synthesis of lipophilic 2,4-diamino-6-

substituted quinazolines and their evaluation as inhibitors of dihydrofolate

reductases and potential antitumor agents. J Med Chem 1998; 41: 3426-3434.

71. Thurmond J, Butchbach MER, Palomo M, Pease B, Rao M, Bedell L et al.

Synthesis and biological evaluation of novel 2,4-diaminoquinazoline

derivatives as SMN2 promoter activators for the potential treatment of spinal

muscular atrophy. J Med Chem 2008; 51: 449-469.

72. Gangjee A, Yu J, Kisliuk RL, Haile WH, Sobrero G, McGuire JJ. Design,

synthesis, and biological activities of classical N-{4-[2-(2-amino-4-ethyl

pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid and its 6-methyl

derivative as potential dual inhibitors of thymidylate synthase and

dihydrofolate reductase and as potential antitumor agents. J Med Chem 2003;

46: 591-600.

73. Gangjee A, Yang J, McGuire JJ, Kisliuk RL. Synthesis and evaluation of a

classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-

oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates. Bioorg Med Chem

2006; 14: 8590-8598.

74. Gangjee A, Yu J, McGuire JJ, Cody V, Galitsky N, Kisliuk RL et al. Design,

synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate

synthase and dihydrofolate reductase as an antitumor agent. J Med Chem

2000; 43: 3837-3851.

75. Gangjee A, Vidwans A, Elzein E, McGuire JJ. Synthesis, antifolate and

antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-

pyrrolo[2,3-d]pyrimidines. J Med Chem 2001; 44: 1993-2003.

359

76. Gangjee A, Lin X, Queener SF. Design, synthesis and biological evaluation of

2,4- diamino -5-methyl -6- substituted pyrrolo [2,3-d] pyrimidines as

dihydrofolate reductase inhibitors. J Med Chem 2004; 47: 3689-3692.

77. Gangjee A, Lin X, Kisliuk RL, McGuire JJ. Synthesis of N-{4-[(2,4-diamino-

5-methyl-4,7-dihydro-3H- pyrrolo [2,3-d] pyrimidin-6-yl) thio] benzoyl}-L-

glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo

[2,3-d] pyrimidin-6-yl) thio] benzoyl}-L-glutamic acid as dual inhibitors of

dihydrofolate reductase and thymidylate synthase and as potential antitumor

agents. J Med Chem 2005; 48: 7215-7222.

78. Gangjee A, Yang J, McGuire JJ, Kisliuk RL. Synthesis and evaluation of a

classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-

oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates. Bioorg Med Chem

2006; 14: 8590-8598.

79. Gangjee A, Li W, Yang J, Kisliuk RL. Design, synthesis, and biological

evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methyl

pyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate

reductase inhibitors. J Med Chem 2008; 51: 68-76.

80. Gangjee A, Adair O, Queener SF. Synthesis of 2,4-diamino-6-(thioarylmethyl)

pyrido[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. Bioorg Med

Chem 2001; 9: 2929-2935.

81. Gangjee A, Zeng Y, McGuire JJ, Kisliuk RL. Synthesis of classical and

nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates. J Med

Chem 2002; 45: 5173-5181.

82. Gangjee A, Adair O, Queener SF. Pneumocystis carinii and Toxoplasma

gondii dihydrofolate reductase inhibitors and antitumor agents: Synthesis and

360

biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)

methyl]-pyrido [2,3-d]pyrimidines. J Med Chem 1999; 42: 2447-2455.

83. Vilaivan T, Saesaengseerung N, Jarprung D, Kamchonwongpaisan S,

Sirawaraporn W, Yuthavong Y. Synthesis of solution phase combinatorial

library of 4,6-diamino-1,2-dihydro-1,3,5-triazine and identification of new

leads against A16v+S108T mutant dihydrofolate reductase of Plasmodium

falciparum. Bioorg Med Chem 2003; 11: 217-224.

84. Khlebnikov AI. The method of frontal polyhedra for conformationally

nonrigid molecules. Quantitative structure-activity relationship in the series of

baker triazines-dihydrofolate reductase inhibitors. Pharm Chem J 1997; 31:

147-154.

85. Maeda S, Kita T, Meguro K. Synthesis of novel 4,6-di(substituted)amino-1,2-

dihydro-1,3,5-triazine derivatives as topical antiseptic agents. J Med Chem

2009; 52: 597-600.

86. Baker BR, Ashton WT. Irreversible enzyme inhibitors. CLXXVI. Active site-

directed irreversible inhibitors of dihydrofolate reductase derived from 4,6-

diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine by ether bridging to a

terminal sulfonyl fluoride. J Med Chem 1970; 13: 1149-1154.

87. Kim KH, Dietrich SW, Hansch C, Dolnick BJ, Bertino JR. Inhibition of

dihydrofolate reductase. 3. 4,6-Diamino-1,2-dihydro-2,2-dimethyl-1-(2-

substituted-phenyl)-s-triazine inhibition of bovine liver and mouse tumor

enzymes. J Med Chem 1980; 23: 1248-1251.

88. Hansch C, Dietrich SW, Fukunaga JY. Inhibition of bovine and rat liver

dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(4-

substituted phenyl)-s-triazines. J Med Chem 1981; 24: 544-549.

361

89. Booth RG, Selassie CD, Hansch C, Santi DV. Quantitative structure-activity

relationship of triazine-antifolate inhibition of leishmania dihydrofolate

reductase and cell growth. J Med Chem 1987; 30: 1218-1224.

90. Leroy D, Kajava AV, Frei C, Gasser SM. Analysis of Etoposide binding to

subdomains of human DNA topoisomerase IIα in the absence of DNA.

Biochemistry 2001; 40: 1624-1634.

91. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT et al.

Glide: A new approach for rapid, accurate docking and scoring. 1. Method

and assessment of docking accuracy. J Med Chem 2004; 47: 1739-1749.

92. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT et al.

Glide: A new approach for rapid, accurate docking and scoring. 2.

Enrichment factors in database screening. J Med Chem 2004; 47: 1750-1759.

93. Krovat EM, Steindl T, Langer T. Recent advances in docking and scoring.

Current Computer Aided Drug Design 2005; 1: 93-102.

94. Leo A, Hansch C, Elkins D. Partition coefficients and their uses. Chem Rev

1971; 71: 525-616.

95. Wilkinson, Andrew M.; McNaught, Alan D. (1997). "Partition Coefficient".

Compendium of Chemical Terminology: IUPAC Recommendations. Oxford:

Blackwell Science.

96. Sangster J. (1997). Octanol-Water Partition Coefficients: Fundamentals and

Physical Chemistry, John Wiley & Sons Ltd. 1997; 2: 178.

97. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernas H, Karlen A.

Correlation of human jejunal permeability (in vivo) of drugs with

experimentally and theoretically derived parameters. A multivariate data

analysis approach. J Med Chem 1998; 41: 4939-4949.

362

98. Liu X, Tu M, Kelly RS, Chen C, Smith BJ. Development of a computational

approach to predict blood-brain barrier permeability. Drug Metab Dispos

2004; 32: 132-139.

99. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1.

Mechanism-based prediction of volume of distribution. J Pharm Sci 2002; 91:

129-156.

100. Kerns EH. High throughput physicochemical profiling for drug discovery. J

Pharm Sci 2001; 90: 1838-1858.

101. Mosmann T. Rapid colorimetric assay for cellular growth and survival:

Application to proliferation and cytotoxicity assays. J Immunol Meth 1983;

65: 55-63.

102. Cancer Cell Culture-method and protocols. Edited by Simon, P. Iandox.2004,

Humana press Inc, 999. Review Drive, Suit 208. Totowa, New Jersey.

103. Peterson LR, Collins SM. Bactericidal testing for infectious disease therapy:

The why and how to measure if we kill the bugs. Clin Microbiol Newsl 2000;

22: 153-157.

104. Venugopal D, Kumar S, Isa M, Bose M. Drug resistance profile of human

Mycobacterium avium complex strains from india. Ind J Med Microbiol 2007;

25: 115-120.

105. Cleidson V, Machado de SS, Elza FAS, Artur S Jr. Screening methods to

determine antibacterial activity of natural products. Braz J Microbiol 2007; 38:

369-380.

106. Brunton LL. In Goodman’s The Pharmacological Basis of Therapeutics’.

Hardman JG, Limberd LE, Molinoff PB, Ruddon RW, Goodman AG. Eds.,

10th ed.; McGraw-Hill: New York, 2001; 1006-1019.

363

107. Roberts S, McDonald IM. In Burger’s Medicinal Chemistry and Drug

Discovery, 6th ed.; Abraham DJ. Ed.; John Wiley: New Jersey, 2003; Vol 4:

86-121.

108. David Son’s Principle and Practice of Medicine, Upper gastrointestinal

disorders, 20th ed : Edinburgh ; New York : Churchill Livingstone, 2006; 863.

109. Herling AW, Weidmann K. In Burger’s Medicinal Chemistry and Drug

Discovery, 5th ed.; Wolff, ME. Ed.; John Wiley: New Jersey, 1996; Vol 2:

122-134.

110. Black JW, Duncan WAM, Durant CJ, Ganellin CR, Parsons EM. Definition

and antagonism of histamine H2-receptors. Nature 1972; 236: 385.

111. Durant GJ, Emmett JC, Ganellin CR. Smith Kline and French Laboratories

Limited. Pharmacologically active guanidine compounds. US Patent

3,950,333. 1976 Apr 13.

112. Price BJ, Clitherow JW, Bradshaw J. Allen and Hanburys Limited.

Aminoalkyl furan derivatives. US Patent 4,128,658. 1978 Dec 5.

113. Kromer W, Positus S, Kruger U. In Pharamceuticals; McGurie JL, Ed.; Wiley-

VCH: Weinhim, 2000; Vol 2:724.

114. Pfeiffer A, Kromer W, Friemann J, Ruge M, Herawi M, Schatzl M et al.

Muscarinic receptors in gastric mucosa are increased in peptic ulcer disease.

Gut 1995; 36: 813-818.

115. Dammann HG, Burkhardt F. Influence of pantoprazole 40 MG and

omeprazole 20 MG on meal-stimulated gastric acid secretion.

Gastroenterology 1998; 114: A98.

116. Lazzaroni M, Sangaletti O, Parente F, Imbimbo BP, Porro BG. Inhibition of

food stimulated acid secretion by association of pirenzepine and ranitidine in

364

duodenal ulcer patients. Int J Clin Pharmacol Ther Toxicol 1986; 24: 685-688.

117. Wyllie JH, Hesselbo T, Black JW. Effects in man of histamine H2-receptor

blockade by burimamide. The Lancet 1972; 300: 1117-1120.

118. Duncan WAM, Parsons ME. Reminiscences of the development of cimetidine.

Gastroenterology 1980; 78: 620-625.

119. Hirata Y, Yanagisawa I, Ishii Y, Tsukamoto S, Ito N, Isomura Y et al.

Yamanouchi Pharmaceutical Co Limited. Guanidino thiazole compounds,

process for the preparation and gastric inhibiting compositions containing

them. US Patent 4,283,408. 1981 Aug 11.

120. Berardi RR, Tankanow RM, Nostrant TT. Comparison of famotidine with

cimetidine and ranitidine. Clin Pharm 1988; 7: 271-284.

121. Pioch RP. EP 49,618, 1985.

122. Shibata K, Etaya T, Yamakoshi N, Kurata S, Koizumi N, Tarutani M et al. EP

24,510 B1 1983.

123. Lin JH. Pharmacokinetic and pharmacodynamic properties of histamine H2-

receptor antagonists. Relationship between intrinsic potency and effective

plasma concentrations. Clin Pharmacokinet 1991; 20: 218-236.

124. Scheuch E, Walter R, Hadasova E, Amon HI, Siegmund W. Influence of H2-

receptor and proton pump inhibitors on some functions of the oxidative and

conjugative drug metabolism. Pharmazie 1996; 51: 493-497.

125. Brittain RT, Daly MJ. A review of the animal pharmacology of ranitidine a

new, selective histamine H2-antagonist. Scand J Gastroenterol Suppl 1981; 69:

1-9.

126. Labenz J. Consequences of Helicobacter pylori cure in ulcer patients.

Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 133-145.

365

127. McCarthy DM. Sucralfate. N Engl J Med 1991; 325: 1017-1025.

128. Collins PW. Misoprostol: Discovery, development, and clinical applications.

Med Res Rev 1990; 10: 149-172.

129. Okamoto CT, Forte JG. Vesicular trafficking machinery, the actin

cytoskeleton, and H+/K+-ATPase recycling in the gastric parietal cell. J

Physiol 2001; 532: 287-296.

130. Ruwart MJ, Nezamis JE, Rush BD, Lancaster C, Davis JP, Nichols NM et al.

Timoprazole is a unique cytoprotective agent in the rat. Digestion 1984; 30:

33-40.

131. Lindberg P, Brandstrom A, Wallmark B, Mattsson H, Rikner L, Hoffmann KJ.

Omeprazole: The first proton pump inhibitor. Med Res Rev 1990; 10: 1-54.

132. Yamada M, Yura T, Morimoto M, Harada T, Yamada K, Honma Y et al.

2-[ (2-Aminobenzyl) sulfinyl]-1-(2-pyridyl)-1,4,5,6-tetrahydrocyclopent [d]

imidazoles as a novel class of gastric H+/K+-ATPase inhibitors. J Med Chem

1996; 39: 596-604.

133. Angela AMCC, Eibert RH, Eijk V, Jacques THM, Cornelis BHWL, Hubert

GML. Determinants of headache in lansoprazole users in the netherlands:

Results from a nested case-control study. Drug Saf 2002; 25: 287-295.

134. Robinson M. Current perspectives on hyper gastrinaemia and

enterochromaffin like cell hyperplasia. Aliment Pharmacol Ther 1999; 13: 5-

10.

135. Ife RJ, Dyke CA, Keeling DJ, Meenan E, Meeson ML, Parson ME et al. 2-[[

(4-Amino-2-pyridyl) methyl] sulfinyl] benzimidazole H+/K+-ATPase

inhibitors. The relationship between pyridine basicity, stability, and activity. J

Med Chem 1989; 32: 1970-1977.

366

136. Weidmann K, Herling AW, Lang HJ, Scheunemann KH, Rippel R,

Nimmesgern H et al. 2-[(2-Pyridylmethyl) sulfinyl]-1H-thieno [3,4-d]

imidazoles. A novel class of gastric H+/K+-ATPase inhibitors. J Med Chem

1992; 35: 438-450.

137. Munson K, Garcia R, Sachs G. Inhibitor and ion binding sites on the gastric

H+/K+-ATPase. Biochemistry 2005; 44: 5267-5284.

138. Suschitzky JL, Wells E. In Comprehensive Medicinal Chemistry; Hansch C.

Ed.; Oxford, Pergamon Press: 2005; 2: 197-202.

139. Lindberg P, Nordberg P, Alminger T, Braendstroem A, Wallmark B. The

mechanism of action of the antisecretory agent omeprazole. J Med Chem

1986; 29: 1327-1329.

140. Esomeprazole. Med Lett Drugs Ther 2001; 43: 36-37.

141. Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors

and acute interstitial nephritis. Clin Gastroenterol Hepatol 2006; 4: 597-604.

142. Gisbert JP, Pajares JM, Losa C. Helicobacter pylori and gastroesophageal

reflux disease: Friends or foes. Hepato gastroenterology 1999; 46: 1023-1029.

143. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection

accelerates healing of reflux esophagitis during treatment with the proton

pump inhibitor pantoprazole. Gasteroenterology 1999; 117: 11-16.

144. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of

the gastric acid pump: The H+/K+-ATPase. Annu Rev Pharmacol Toxicol

1995; 35: 277-305.

145. Stedman CA, Barclay ML. Comparison of the pharmacokinetics, acid

suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther

2000; 14: 963-978.

367

146. Sharma VK, Peyton B, Spears T, Raufman JP, Howden CW. Oral

pharmacokinetics of omeprazole and lansoprazole after single and repeated

doses as intact capsules or as suspensions in sodium bicarbonate. Aliment

Pharmacol Ther 2000; 14: 887-892.

147. Monthly Index of Medical Specialties. Duncan C. Ed.;Hay London, Market

Publishing Services: 2002.

148. Becker JC, Grosser N, Waltke C, Schulz S, Erdmann K, Domschke W et al.

Beyond gastric acid reduction: Proton pump inhibitors induce heme

oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun

2006; 345: 1014-1021.

149. Simon WA, Sturm E, Hartmann HJ, Weser U. Hydroxyl radical scavenging

reactivity of proton pump inhibitors. Biochem Pharmacol 2006; 71: 1337-

1341.

150. Katagiri F, Inoue S, Sato Y, Itoh H, Takeyama M. Comparison of the effects

of proton pump inhibitors on human plasma adrenocorticotropic hormone

and cortisol levels under the starved condition. Biomed Pharamacother 2006;

60: 109-112.

151. Tsukimi Y, Ushiro T, Yamazaki T, Ishikawa H, Hirase J, Narita M et al.

Studies on the mechanism of action of the gastric H+/K+-ATPase inhibitor

SPI-447. Jpn J Pharmacol 2000; 82: 21-28.

152. Keeling DJ, Laing SM, Bilfinger JS. SCH 28080 is a lumenally acting, K+-site

inhibitor of the gastric H+/K+-ATPase. Biochem Pharmacol 1988; 37: 2231-

2236.

153. Wallmark B, Briving C, Fryklund J, Munson K, Jackson R, Mendlein J et al.

Inhibition of gastric H+\K

+-ATPase and acid secretion by SCH 28080, a

368

substituted pyridyl(1,2a)imidazole. J Biol Chem 1987; 262: 2077-2084.

154. Uchiyama K, Wakatsuki D, Kakinoki B, Takeuchi Y, Araki T, Morinaka Y.

The long-lasting effect of TU-199, a novel H+\K

+-ATPase inhibitor, on gastric

acid secretion in dogs. J Pharm Pharmacol 1999; 51: 457-464.

155. Sachs G, Chang HH, Rabon E, Shackman R, Lewin M, Saccomani G. A

nonelectrogenic H+ pump in plasma membranes of dog stomach. J Biol Chem

1976; 251: 7690-.7698

156. Clissold SP, Campoli Richards DM. Omeprazole. A preliminary review of its

pharmacodynamic and pharmacokinetic properties, and therapeutic potential in

peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986; 32: 15-47.

157. Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G. Pharmacology and

toxicology of omeprazole with special reference to the effects on the gastric

mucosa. Scand J Gastroenterol 1986; 21(Suppl. 118): 31-38.

158. Hakanson R, Sunder F. Gastric carcinoids and antisecretory drugs. Trends

Pharmacol Sci 1986; 7: 386-387.

159. Pope AJ, Parsons ME. Reversible inhibitors of the gastric H+/K+-transporting

ATPase: A new class of anti-secretory agent. Trends Pharmacol Sci 1993; 14:

323-325.

160. LaMattina JL, McCarthy PA, Reiter LA, Holt WF, Yeh LA. Antiulcer agents.

4-Substituted 2-guanidinothiazoles: Reversible, competitive and selective

inhibitors of gastric H+/K+-ATPase. J Med Chem 1990; 33: 543-552.

161. Woo TW, Chang MS, Chung YK, Kim KB, Sohn SK, Kim SG et al. Effects of

YJA20379-4 on gastric secretion, helicobacter pylori growth and various

gastric and duodenal lesions in rats. Biol Pharm Bull 1998; 21: 449-455.

369

162. Kim KB, Park SH, Lee JM, Choi WS, Paek JH, Seo KH et al. WO 9703077,

1997.

163. Yoon SH, Seo S, Lee YH, Hwang SK, Kim DY. Syntheses of 2-[(3,5-

dimethyl-4-methoxypyridyl)alkyl]-benzothiazolidine derivatives as a potential

gastric H+/K+-ATPase inhibitor. Bioorg Med Chem Lett 1998; 8: 1909-1912.

164. Sih JC, Im WB, Robert A, Graber DR, Blakeman DP. Studies on (H+-K+)-

ATPase inhibitors of gastric acid secretion. Prodrugs of 2-[(2-pyridinyl

methyl) sulfinyl] benzimidazole proton-pump inhibitors. J Med Chem 1991;

34: 1049-1062.

165. Nelson KS, Krasso A, Muller RM, Fischli AE. Ro 18-5364, a potent new

inhibitor of the gastric H+\K

+-ATPase. Eur J Biochem 1987; 166: 453-459.

166. Yoo HY, Chung KJ, Chai JP, Chang MS, Kim SG, Choi WS, Kim YH, Chun

JK, Chung YK, Kim YH, Paek JH, Seo KH, Kang DP. EP 843681, 2002.

167. Shin JM, Sachs G, Cho Y, Garst M. 1-Arylsulfonyl-2-(pyridylmethylsulfinyl)

benzimidazoles as new proton pump inhibitor prodrugs. Molecules 2009; 14:

5247-5280.

168. Uchida M, Chihiro M, Morita S, Yamashita H, Yamasaki K, Kanbe T et al.

Synthesis and antiulcer activity of 4-substituted 8-[(2-benzimidazolyl)

sulfinylmethyl]-1,2,3,4-tetra-hydroquinolines and related compounds. Chem

Pharm Bull 1990; 38: 1575-1586.

169. Yamada S, Goto T, Yamaguchi T, Aihara K, Kogi K, Narita S. Synthetic

study of 2-[(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-sulfinyl]-1H-

benzimidazole analogs and their biological properties as novel proton pump

inhibitors. Chem Pharm Bull 1995; 43: 421-431.

370

170. Terashima K, Sato M, Ono M, Muraoka O. Synthesis and mechanism of

action of ethyl-2-[(1H benzimidazol-2-yl)sulfinylmethyl]-4-dimethyl amino-5-

pyridine carboxylate, a New H+/K+-ATPase inhibitor associated with

Mucosal Protective Activity, AFMC, Medicinal Chemistry Symposium, 1995.

171. Tsukahara T, Takahashi S, Okabe S. Gasteroenterology 1996; 110: A281.

172. Weidmann K, Herling AW, Lang HJ, Scheunemann KH, Rippel R,

Nimmesgern H et al. 2-[(2-Pyridylmethyl)sulfinyl]-1H-thieno[3,4-

d]imidazoles. A novel class of gastric H+\K

+-ATPase. J Med Chem 1992; 35:

438-450.

173. Terauchi H, Tanitame A, Tada K, Nakamura K, Seto Y, Nishikawa Y.

Nicotinamide derivatives as a new class of gastric H+/K+-ATPase inhibitors.

1. Synthesis and structure-activity relationships of N-substituted 2-

(benzhydryl and benzylsulfinyl) nicotinamides. J Med Chem 1997; 40: 313-

321.

174. Berzsenyi P, Sebestyen L, Meresz MM, Andrasi F. GYKI 34 655: A potent

gastric antisecretory and antiulcer/cytoprotective drug. Pharmacol Res 1995;

31: 94.

175. Mora CC. Piperazines. US Patent 4,278,796. 1981 Jul 14.

176. Murai H, Ohata K, Aoyagi Y, Ueda F, Kitano M, Takata S et al. Nippon

Shinyaku Co Ltd. Benzoguanamine derivatives. US Patent 3,966,728. 1976

June 29.

177. Hirosada S, Watanable M, Mitsuru K, Isuke I. EP 0,00,3084, 1982.

178. Otsubo K, Morita S, Uchida M, Yamasaki K, Kanbe T, Shimizu T. Synthesis

and antiulcer activity of optical isomers of 2-(4-chlorobenzoylamino)-3-

[2(1H)-quinolinon-4-yl] propionic acid (Rebamipide). Chem Pharm Bull 1991;

371

39: 2906-2909.

179. Miki T, Asano M, Hosokami T. EP 0,185,368, 1990; Chem Abstr 1986; 105:

172063.

180. Hino K, Kawashima K, Oka M, Nagai Y, Uno H, Matsumoto J. A novel class

of antiulcer agents. 4-Phenyl-2-(1-piperazinyl)quinolines. Chem Pharm Bull

1989; 37: 110-115.

181. Katano K, Tomomoto T, Ogino H, Yamazaki N, Hirano F, Yuda Y. EP

0,405,976, 1995; Chem Abstr 1991; 114: 228904.

182. OECD 2001-guideline on acute oral toxicity (AOT) Environmental health and

safety monograph series on testing and adjustment No.425.

183. Paget GE, Barnes JM. “Evaluation Drug Activities and Pharmacokinetics”,

Laurance DR, Bachrach AC. New York: Academic Press 1983 Vol-1.

184. Vogel GH, Vogel WH. Drug discovery and evaluation of pharmacological

assays, 2nd ed, Germany, Springer vealag Berlin Heeidelberg, 1997; 486-490.

185. Kulakarni SK. Hand book of exp Kulkarni SK. Hand book of experimental

pharmacology, 3rd ed, Punjab University Chandigarh, Vallabh Prakashan 148-

150.

186. Shay H, Komarov SA, Fels SS, Meeranze D, Gruenstein M, Siplet H. A

simple method for the uniform production of gastric ulceration.

Gastroenterology 1945; 5: 43-61.

187. Hawk PB, Oser B, Summerson WH. Practical Physiological Chemistry (12th

ed.) 1947; 579- 589. The Blakiston Co., Philadelphia.

188. Thangam C, Dhananjayam R. Antiinflammatory potential of the seeds of

Carum Copticum Linn. Indian J Pharmacol 2003; 38: 388.

372

189. Cotran RS, Kurma V, Collins T, Robbins. Pathological basis of disease 6th ed.,

New York; W.B Saunder’s Company, 2001.

190. Kavimani S, Vetrichalvan T, Nagarajan NS. Indian Drugs 2002; 99: 161.

191. Banerjee S, Kumar ST, Mandal S, Chandra DP, Sikdar S. Assessment of the

anti-inflammatory effects of Swertia chirata in acute and chronic experimental

models in male albino rats. Indian J Pharmacol 2000; 32: 21.